교모세포종(GBM) : 신규 요법, 미충족 수요 및 TPP 인사이트 보고서(2026년)

Glioblastoma (GBM) Emerging Therapy and TPP Insights

Thelansis's "Glioblastoma (GBM) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Glioblastoma (GBM) Overview

Glioblastoma is the most common primary malignant brain tumor in adults, defined strictly under the current WHO classification as an IDH-wildtype diffuse astrocytic glioma. It is characterized by microvascular proliferation, intense therapeutic resistance, and pseudopalisading necrosis. Driven by genomic alterations like EGFR amplification and TERT promoter mutations, its management is heavily influenced by MGMT promoter methylation status, which serves as a vital predictive biomarker for alkylating chemotherapy response rather than an oncogenic driver. Patients present with progressive headaches, seizures, and focal neurological deficits. Diagnosis relies on contrast-enhanced brain MRI showing a heterogeneously enhancing ring lesion, confirmed via histopathology. Standard frontline care utilizes maximal safe resection followed by radiotherapy and concurrent temozolomide, supplemented by tumor-treating fields. For recurrent disease, the investigational frontier focuses on combination checkpoint blockade, CAR-T platforms, dendritic cell vaccines, and oncolytic viruses within clinical trials. Median survival remains constrained at fifteen months, shifting dynamically based on age, performance status, and MGMT methylation.

Key Highlights

• In France, diagnosed GBM cases are projected to increase from 2,493 in 2025 to 2,713 by 2035.
• GBM remains the most aggressive primary malignant brain tumor in adults.
• Despite multimodal treatment, prognosis remains poor with frequent recurrence.
• Significant unmet need exists for therapies capable of improving overall survival.

Market Overview

• The Italy GBM market is projected to grow from $141.75M in 2025 to $231M by 2035.
• Market growth is driven by:
• Increased adoption of targeted and immunotherapeutic approaches
• Continued investment in novel oncology platforms
• Future growth will depend on breakthrough therapies capable of overcoming treatment resistance.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Theragnostics Ltd.
• BeyondBio Inc.
• Katmai Pharmaceuticals Inc.
• NuvOx LLC
• NeuGATE Theranostics
• Neonc Technologies, Inc.
• CNS Pharmaceuticals, Inc.
• Laminar Pharmaceuticals
• Aveta Biomics, Inc.
• Chimeric Therapeutics
• Jecho Biopharmaceuticals Co., Ltd.
• Stemline Therapeutics, Inc.
• Telix Pharmaceuticals (Innovations) Pty Limited
• Alaunos Therapeutics
• Tetragon Biosciences Ltd.
• Kintara Therapeutics, Inc.
• Orbus Therapeutics, Inc.
• CarThera
• Diakonos Oncology Corporation
• Starlight Therapeutics Inc.
• Myosin Therapeutics Inc.
• Phost'In Therapeutics
• Black Diamond Therapeutics, Inc.
• Tango Therapeutics, Inc.
• Sapience Therapeutics
• GlaxoSmithKline
• Apollomics Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)